Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Doxycycline Placebo Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

NCT01375491
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 7, 2026, 7:23 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of Treatments on Atopic Dermatitis

NCT01631617
View directory record Official record
Conditions
Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic, Skin Diseases
Interventions
Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline, Sodium hypochlorite, Placebo capsules, Placebo Sodium hypochlorite
Drug · Other
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 50 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

Treating Periodontal Infection: Effects on Glycemic

NCT00016835
View directory record Official record
Conditions
Periodontal Disease, Diabetes Mellitus, Type 2
Interventions
Supra-gingival scaling and placebo, Subgingival scaling and metronidazole, Subgingival scaling and doxycycline
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00612573
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
12 Years to 45 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
23
States / cities
Encino, California • Fremont, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

NCT05343455
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Santa Monica, California • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 7, 2026, 7:23 AM EDT
Withdrawn Phase 4 Interventional

Doxycycline Outcomes in Lupus Erythematosus

NCT01014260
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Placebo, Doxycycline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

NCT00764361
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
doxycycline, placebo gel
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 7, 2026, 7:23 AM EDT
Recruiting Phase 2 Interventional

MMP-9 Inhibition for Recalcitrant Wet AMD

NCT04504123
View directory record Official record
Conditions
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Doxycycline Hyclate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)

NCT00358462
View directory record Official record
Conditions
Urethritis
Interventions
Azithromycin, Doxycycline
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years and older · Male only
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cholera Anti-Secretory Treatment Trial

NCT04150250
View directory record Official record
Conditions
Cholera
Interventions
iOWH032, Placebo, V. cholerae Challenge, Antibiotics
Drug · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 44 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

NCT05296629
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
27
States / cities
Rogers, Arkansas • Cerritos, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 1 Interventional

Influence of MMP on Brain AVM Hemorrhage

NCT00783523
View directory record Official record
Conditions
Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
Interventions
Doxycycline or Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 7, 2026, 7:23 AM EDT
Active, not recruiting Phase 2 Interventional

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

NCT05382208
View directory record Official record
Conditions
Emphysema, HIV
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 7, 2026, 7:23 AM EDT
Withdrawn Phase 2 Interventional

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

NCT04433078
View directory record Official record
Conditions
Cytokine Storm, SARS-CoV-2
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

NCT00322465
View directory record Official record
Conditions
Urethritis
Interventions
Doxycycline, Placebo, Tinidazole, Azithromycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Male only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Continuous Oral Contraceptives and Doxycycline

NCT00480532
View directory record Official record
Conditions
Contraceptives, Oral
Interventions
Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 4 Interventional

Ocular Rosacea Biome Study

NCT05296837
View directory record Official record
Conditions
Ocular Rosacea, Antimicrobial Resistance
Interventions
Doxycycline 40 MG ( 20mg twice daily), Doxycycline 200 MG ( 100 mg twice daily), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 7, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional Results available

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT02569437
View directory record Official record
Conditions
Polyp of Nasal Sinus
Interventions
Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703
View directory record Official record
Conditions
Blepharitis, Meibomianitis, Dry Eye
Interventions
COL-101 (doxycycline, USP) capsules, placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

NCT01320033
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD2475/101 40 mg, Doxycycline 100 mg, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 7, 2026, 7:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Doxycycline in Humans

NCT00964834
View directory record Official record
Conditions
Anthrax
Interventions
Doxycycline and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Sep 7, 2026, 7:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial

NCT02456662
View directory record Official record
Conditions
Drug-induced Nausea and Vomiting
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Sep 7, 2026, 7:23 AM EDT